GURUFOCUS.COM » STOCK LIST » Asia » Malaysia » XKLS » Duopharma Biotech Bhd (XKLS:7148) » Definitions » 5-Year EBITDA Growth Rate
Switch to:

Duopharma Biotech Bhd (XKLS:7148) 5-Year EBITDA Growth Rate

: 12.60% (As of Sep. 2022)
View and export this data going back to 2002. Start your Free Trial

Duopharma Biotech Bhd's EBITDA per Share for the three months ended in Sep. 2022 was RM0.04.

During the past 12 months, Duopharma Biotech Bhd's average EBITDA Per Share Growth Rate was 3.00% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 7.70% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 12.60% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 5.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Duopharma Biotech Bhd was 20.20% per year. The lowest was -6.40% per year. And the median was 5.50% per year.


Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Duopharma Biotech Bhd's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Duopharma Biotech Bhd 5-Year EBITDA Growth Rate Distribution

For the Drug Manufacturers industry and Healthcare sector, Duopharma Biotech Bhd's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Duopharma Biotech Bhd's 5-Year EBITDA Growth Rate falls in comparison to its industry or sector. The grey bar indicates the 5-Year EBITDA Growth Rate's extreme value range as defined by GuruFocus.



Duopharma Biotech Bhd 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Duopharma Biotech Bhd  (XKLS:7148) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.


Duopharma Biotech Bhd 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Duopharma Biotech Bhd's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Duopharma Biotech Bhd (XKLS:7148) Business Description

Duopharma Biotech Bhd logo
Traded in Other Exchanges
N/A
Address
Lot 2599, Jalan Seruling 59, Kawasan 3, Taman Klang Jaya, Klang, MYS, 41200
Duopharma Biotech Bhd is an investment holding company engaged in manufacturing pharmaceuticals. It develops, manufactures, and markets generic and over-the-counter pharmaceutical products. The operating segment of the company is the manufacturing and distribution of pharmaceutical products. The principal activities of its subsidiary are to carry out business as a manufacturer, distributor, importer and exporter of pharmaceutical products and medicines.

Duopharma Biotech Bhd (XKLS:7148) Headlines

No Headlines